Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Certara Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Certara (CERT – Research Report) and Gilead Sciences...

Analysts’ Top Healthcare Picks: Certara (CERT), Gilead Sciences (GILD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Certara (CERT – Research Report) and Sera Prognostic...

Analysts Are Bullish on Top Healthcare Stocks: Certara (CERT), Sera Prognostics (SERA)

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Certara, with a price target of $14.00. Sergott covers the Health...

Barclays Sticks to Their Buy Rating for Certara (CERT)

Cerrado Gold Inc ( ($CRDOF) ) has released its Q3 earnings. Here is a breakdown of the information Cerrado Gold Inc presented to its investors. Cer...

Cerrado Gold Reports Q3 2025 Financial Results

An announcement from Cerrado Gold ( ($TSE:CERT) ) is now available. Cerrado Gold reported a strong third quarter in 2025 with a gold equivalent pro...

Current Quarter	$0.07	Next Quarter	$0.08
Current Year	$0.3	Next Year	$0.35
QoQ Growth	+14.3%	YoY Growth	+16.7%
3Y EPS CAGR	+3.9%	Target Price	$12.88
Consensus	Buy	Upside	+44.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CERT	$8.91	-0.67%	730.26K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CERT	$8.91	-0.7%	730.26K
3
4
5
6

CERT

CERT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Certara Inc. Data in Excel

Get Certara Inc. Data in Excel